1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Sunsho Acquisition Finally Paying Off For Towa

Profits Rose Dramatically For Towa Amid Hostile Business Environment For Japanese Generics

 
• By Chloe Kent

After several lackluster quarters, Towa’s acquisition of Sunsho Pharmaceutical is finally paying off for the Japanese generics firm.

Decreasing percentage symbols transferring into increasing cash symbols
Towa's investment into Sunsho Pharmaceutical is finally beginning to pay off • Source: Shutterstock

A strong performance in its native business and the EU, alongside depreciation of the yen, allowed Japanese generics firm Towa Pharmaceutical Co. Ltd. to deliver a standout first quarter, after experiencing something of a rough ride during the previous financial year.

Net sales in the domestic segment were up 19.2% year on year, to ¥43bn ($295m), due to sales growth of new Towa products and strong sales stemming from value added medicines subsidiary Sunsho Pharmaceutical. The Sunsho sales have come as a relief to both the firm and investors after several quarters in which the acquisition took a toll on the firm’s bottom line

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

More from Business